ERBB2 and breast cancer: Differences in guidelines further include the HER2-low category, wherein the 2018 ASCO/CAP breast cancer guidelines include faint membranous labeling in ≤10% within a score of 0, whereas ISGyP and FDA guidance defines a score of 0 as absolutely no staining.